| Symbol | CARM |
|---|
| Name | CARISMA THERAPEUTICS, INC. |
|---|
| Sector | HEALTH CARE |
|---|
| Region | North America |
|---|
| Industry | - |
|---|
| Address | 19104 United States PA 3675 Market Street Suite 401 |
|---|
| Telephone | (267) 491-6422 |
|---|
| Fax | — |
|---|
| Email | — |
|---|
| Website | https://carismatx.com/ |
|---|
| Incorporation | US |
|---|
| Incorporated On | 2016 |
|---|
| Employees | — |
|---|
| Fiscal Year | 12/31 |
|---|
| Public Since | — |
|---|
| Exchanges | OTC;NASDAQ |
|---|
| Auditor | KPMG LLP - New York, New York, (USA); |
|---|
| Audit Status | AUDITED |
|---|
| Reporting Status | Dark: Alternative Reporting Standard |
|---|
| CIK | 0001485003 |
|---|
| Description | Carisma Therapeutics, Inc. is a biopharmaceutical company headquartered in Philadelphia, PA. Its primary activity involves research, development, and manufacturing of cell-based immunotherapies for solid tumors and other serious diseases, with recent efforts focusing on an in vivo CAR-M platform in partnership with Moderna.
Additional info from NASDAQ:
Carisma Therapeutics Inc. is a clinical-stage cell therapy company. The Company is focused on utilizing the Companys macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The Company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells. The Companys lead product candidate, CT-0508, is a Chimeric Antigen Receptor Macrophage (CAR-M) to be evaluated in a human clinical trial and is intended to treat solid tumors that overexpress HER2. The Companys second product candidate, CT-0525, is also intended to treat solid tumors that overexpress HER2, is in preclinical development. Beyond CT-0508 and CT-0525, the Company has a pipeline of cell therapy assets in various stages of pre-clinical development. The Company is also developing in vivo CAR-M gene therapies.
Additional info from OTC:
Carisma Therapeutics, Inc. is a biopharmaceutical company headquartered in Philadelphia, PA. Its primary activity involves research, development, and manufacturing of cell-based immunotherapies for solid tumors and other serious diseases, with recent efforts focusing on an in vivo CAR-M platform in partnership with Moderna. |
|---|
2026-04-23 15:45
Carmila: First-Quarter 2026 Financial Information
Read more
2026-04-23 15:45
Carmila : Information financière au 31 mars 2026
Read more
2026-04-22 09:46
Carmila : Modalités de mise à disposition ou de consultation des documents préparatoires à l’Assemblée Générale Mixte du 13 mai 2026
Read more
2026-04-22 09:46
Carmila: Availability of Documents for the Ordinary and Extraordinary Shareholder Meeting on 13 May 2026
Read more
2026-04-02 15:40
CARMILA: Information Concerning the Total Number of Voting Rights and Share
Read more
2026-04-02 15:40
CARMILA : Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L.233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des marchés financiers
Read more
2026-04-01 14:02
Carmila Makes its 2025 Universal Registration Document Available
Read more
2026-04-01 14:02
Carmila met à disposition son Document d’enregistrement universel 2025
Read more
2025-12-05 16:16
Carisma Announces Delisting from Nasdaq and SEC Deregistration
Read more
2025-10-13 08:13
Carisma Therapeutics Inc (CARM) was removed from the list of traded instruments on NASDAQ exchange
Read more
No clinical trials found for this company.
No clinical products found for this company.